Should I buy or sell RxSight stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for RxSight in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RXST shares. View RXST analyst ratings or view top-rated stocks .

What is RxSight's stock price target for 2024?

6 brokers have issued 12 month price targets for RxSight's shares. Their RXST share price targets range from $32.00 to $64.00. On average, they expect the company's share price to reach $49.63 in the next year. This suggests that the stock has a possible downside of 4.1%. View analysts price targets for RXST or view top-rated stocks among Wall Street analysts .

How have RXST shares performed in 2024?

RxSight's stock was trading at $40.32 at the start of the year. Since then, RXST shares have increased by 28.3% and is now trading at $51.75. View the best growth stocks for 2024 here .

When is RxSight's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our RXST earnings forecast .

How were RxSight's earnings last quarter?

RxSight, Inc. (NASDAQ:RXST) announced its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.10. The company earned $28.58 million during the quarter, compared to analyst estimates of $28.60 million. RxSight had a negative net margin of 54.57% and a negative trailing twelve-month return on equity of 31.16%.

What ETFs hold RxSight's stock?

ETFs with the largest weight of RxSight (NASDAQ:RXST) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE) . iShares Micro-Cap ETF (IWC) .

What guidance has RxSight issued on next quarter's earnings?

RxSight issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $128.0 million-$135.0 million, compared to the consensus revenue estimate of $128.6 million.

When did RxSight IPO?

RxSight (RXST) raised $125 million in an initial public offering on Friday, July 30th 2021. The company issued 7,350,000 shares at a price of $16.00-$18.00 per share.

Who are RxSight's major shareholders?

RxSight's stock is owned by a variety of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.51%), Counterpoint Mutual Funds LLC (0.04%) and MCIA Inc (0.02%). Insiders that own company stock include Bakker Juliet Tammenoms, Eric Weinberg, Ilya Goldshleger, Jesse Anderson Corley , Robert Keith Warner, Ronald M Md Kurtz, Shelley B Thunen, Shweta Maniar and William J Phd Link. View institutional ownership trends .

How do I buy shares of RxSight?

Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RXST

RxSight (RXST) Stock Price, News & Analysis

→ This company has increased its dividend every year for 54 years (From DTI) (Ad)

Free RXST Stock Alerts

$51.75

-1.08 (-2.04%)

(As of 04/18/2024 ET)

Compare

Today's Range: $50.95
▼
$53.08
50-Day Range: $46.20
▼
$57.92
52-Week Range: $17.00
▼
$58.21

Volume: 397,195 shs
Average Volume: 437,776 shs
Market Capitalization: $1.91 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $49.63

Get RxSight alerts:

RxSight MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 4.1% Downside
$49.63 Price Target
Short Interest: Healthy
4.17% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.56
Based on 3 Articles This Week
Insider Trading: Selling Shares
$7.28 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.94) to ($0.91) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.49 out of 5 stars

Medical Sector

690th out of 918 stocks

Medical Devices Industry

4th out of 5 stocks

1.5

Analyst's Opinion

Consensus Rating
RxSight has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
RxSight has only been the subject of 4 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.17% of the float of RxSight has been sold short.
Short Interest Ratio / Days to Cover
RxSight has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in RxSight has recently decreased by 0.77%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
RxSight does not currently pay a dividend.
Dividend Growth
RxSight does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RXST.

2.0

News and Social Media Coverage

News Sentiment
RxSight has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for RxSight this week, compared to 2 articles on an average week.
Search Interest
Only 4 people have searched for RXST on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added RxSight to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, RxSight insiders have sold 1,690.25% more of their company's stock than they have bought. Specifically, they have bought $406,680.00 in company stock and sold $7,280,585.00 in company stock.
Percentage Held by Insiders
21.13% of the stock of RxSight is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
78.78% of the stock of RxSight is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for RxSight are expected to grow in the coming year, from ($0.94) to ($0.91) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of RxSight is -36.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of RxSight is -36.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
RxSight has a P/B Ratio of 11.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

With the “Bitcoin Loophole” you can supercharge the gains by 10x or more

Thanks to this newly discovered Bitcoin Loophole, you can now trade Bitcoin in any regular brokerage account… And not only that… you can use it to supercharge the gains of Bitcoin by 10x or more! You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history. That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords…

About RxSight Stock (NASDAQ:RXST)

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

RXST Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RXST Stock News Headlines

April 3, 2024 | insidertrades.com

RxSight, Inc. (NASDAQ:RXST) CFO Shelley B. Thunen Sells 20,000 Shares

April 16, 2024 | americanbankingnews.com

RxSight, Inc. (NASDAQ:RXST) Given Consensus Rating of "Buy" by Analysts

April 18, 2024 | Insiders Exposed (Ad)

This consistently signaled gains of 453%... 610%... and even 1036%...

It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.

April 13, 2024 | americanbankingnews.com

Needham & Company LLC Reiterates Buy Rating for RxSight (NASDAQ:RXST)

April 11, 2024 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Abivax SA Sponsored ADR (ABVX), RxSight (RXST) and Clearside Biomedical (CLSD)

April 11, 2024 | markets.businessinsider.com

Assessing RxSight: Insights From 8 Financial Analysts

April 6, 2024 | investing.com

RxSight launches new Light Adjustable Lens product

April 4, 2024 | globenewswire.com

RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting

April 18, 2024 | DTI (Ad)

Don’t expose yourself to stocks during the week

The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.

March 27, 2024 | globenewswire.com

RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference

March 14, 2024 | morningstar.com

RxSight Inc RXST

March 4, 2024 | markets.businessinsider.com

Patrick Wood Reaffirms Buy Rating for RxSight Amid Strong Growth and Market Expansion Potential

March 3, 2024 | ca.finance.yahoo.com

RXST Mar 2024 70.000 call

March 2, 2024 | finance.yahoo.com

RxSight, Inc. (NASDAQ:RXST) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.75

March 1, 2024 | finance.yahoo.com

RxSight Full Year 2023 Earnings: EPS Beats Expectations

February 29, 2024 | markets.businessinsider.com

Stifel Nicolaus Reaffirms Their Buy Rating on RxSight (RXST)

February 29, 2024 | markets.businessinsider.com

Oppenheimer Reaffirms Their Buy Rating on RxSight (RXST)

February 29, 2024 | globenewswire.com

RxSight, Inc. to Participate in the 34th Annual Oppenheimer Healthcare Conference

February 29, 2024 | markets.businessinsider.com

Buy Rating on RxSight: Strong Financials and Positive 2024 Outlook Drive Upward Price Target

February 29, 2024 | finance.yahoo.com

RxSight, Inc. (NASDAQ:RXST) Q4 2023 Earnings Call Transcript

February 29, 2024 | markets.businessinsider.com

Forecasting The Future: 9 Analyst Projections For RxSight

February 28, 2024 | benzinga.com

Recap: RxSight Q4 Earnings

February 28, 2024 | msn.com

RxSight Non-GAAP EPS of -$0.13 beats by $0.14, revenue of $28.6M beats by $0.74M

February 28, 2024 | finance.yahoo.com

RxSight Inc (RXST) Reports Significant Revenue Growth in Q4 and Full Year 2023

February 28, 2024 | globenewswire.com

RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

February 24, 2024 | msn.com

RxSight (RXST) Price Target Increased by 12.18% to 50.49

February 18, 2024 | finance.yahoo.com

RXST Mar 2024 40.000 put

See More Headlines

Receive RXST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Ophthalmic goods
Sub-Industry: N/A
Current Symbol: NASDAQ:RXST
CUSIP: N/A
CIK: 1111485
Web: www.rxsight.com
Phone: 949-521-7830
Fax: N/A
Employees: 374
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $49.63
High Stock Price Target: $64.00
Low Stock Price Target: $32.00
Potential Upside/Downside: -4.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.43)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-48,610,000.00
Net Margins: -54.57%
Pretax Margin: -54.55%
Return on Equity: -31.16%
Return on Assets: -25.51%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.06
Quick Ratio: 7.22

Sales & Book Value

Annual Sales: $89.08 million
Price / Sales: 21.49
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.47 per share
Price / Book: 11.58

Miscellaneous

Outstanding Shares: 36,990,000
Free Float: 29,172,000
Market Cap: $1.91 billion
Optionable: Optionable
Beta: 1.22

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Ronald M. Kurtz M.D. (Age 61)
President, CEO & Director
Comp: $1.03M
Ms. Shelley B. Thunen (Age 70)
Chief Financial Officer
Comp: $651.36k
Dr. Ilya Goldshleger Ph.D. (Age 49)
Chief Operating Officer
Comp: $657.81k
Mr. Eric J. Weinberg (Age 63)
Chief Commercial Officer
Comp: $638.9k
Ms. Rebecca Williston
Vice President of Accounting & Finance
Mr. Matt Haller Ph.D.
Chief Technology Officer
Alex Huang
Investor Relations
Mr. Roy Freeman
Vice President of Marketing
Ms. Caroline Vaughn
Vice President of Human Resources
Mr. Scott Gaines
Senior VP of Commercial Operations & Business Process

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RXST Stock Analysis - Frequently Asked Questions

Should I buy or sell RxSight stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for RxSight in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RXST shares.
View RXST analyst ratings or view top-rated stocks.
What is RxSight's stock price target for 2024?: 6 brokers have issued 12 month price targets for RxSight's shares. Their RXST share price targets range from $32.00 to $64.00. On average, they expect the company's share price to reach $49.63 in the next year. This suggests that the stock has a possible downside of 4.1%.
View analysts price targets for RXST or view top-rated stocks among Wall Street analysts.
How have RXST shares performed in 2024?: RxSight's stock was trading at $40.32 at the start of the year. Since then, RXST shares have increased by 28.3% and is now trading at $51.75.
View the best growth stocks for 2024 here.
When is RxSight's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RXST earnings forecast.
How were RxSight's earnings last quarter?: RxSight, Inc. (NASDAQ:RXST) announced its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.10. The company earned $28.58 million during the quarter, compared to analyst estimates of $28.60 million. RxSight had a negative net margin of 54.57% and a negative trailing twelve-month return on equity of 31.16%.
What ETFs hold RxSight's stock?: ETFs with the largest weight of RxSight (NASDAQ:RXST) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE).iShares Micro-Cap ETF (IWC).

What guidance has RxSight issued on next quarter's earnings?: RxSight issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $128.0 million-$135.0 million, compared to the consensus revenue estimate of $128.6 million.
When did RxSight IPO?: RxSight (RXST) raised $125 million in an initial public offering on Friday, July 30th 2021. The company issued 7,350,000 shares at a price of $16.00-$18.00 per share.
Who are RxSight's major shareholders?: RxSight's stock is owned by a variety of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.51%), Counterpoint Mutual Funds LLC (0.04%) and MCIA Inc (0.02%). Insiders that own company stock include Bakker Juliet Tammenoms, Eric Weinberg, Ilya Goldshleger, Jesse Anderson Corley, Robert Keith Warner, Ronald M Md Kurtz, Shelley B Thunen, Shweta Maniar and William J Phd Link.
View institutional ownership trends.
How do I buy shares of RxSight?: Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RXST) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

RxSight (RXST) Stock Price, News & Analysis

RxSight MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About RxSight Stock (NASDAQ:RXST)

RXST Stock Price History

RXST Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

RXST Stock Analysis - Frequently Asked Questions

Overall MarketRank^™